enGene (NASDAQ:ENGN) Sees Large Volume Increase

enGene Holdings Inc. (NASDAQ:ENGN) saw unusually-high trading volume on Friday . Approximately 99,116 shares traded hands during trading, an increase of 116% from the previous session’s volume of 45,947 shares.The stock last traded at $16.00 and had previously closed at $15.32.

Analysts Set New Price Targets

ENGN has been the topic of a number of research analyst reports. SVB Leerink assumed coverage on enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target on the stock. UBS Group started coverage on enGene in a report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Morgan Stanley initiated coverage on shares of enGene in a report on Friday, March 8th. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, Wells Fargo & Company initiated coverage on shares of enGene in a research note on Monday, April 22nd. They set an “overweight” rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, enGene has a consensus rating of “Buy” and an average target price of $34.40.

enGene Stock Up 1.2 %

The business has a fifty day simple moving average of $16.21.

Insider Buying and Selling

In related news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the business’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $15.01, for a total transaction of $68,670.75. Following the sale, the insider now owns 3,084,107 shares of the company’s stock, valued at $46,292,446.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ENGN. Fcpm Iii Services B.V. bought a new position in shares of enGene during the fourth quarter valued at $80,097,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter valued at about $10,441,000. BVF Inc. IL purchased a new position in enGene in the fourth quarter worth about $20,777,000. Finally, Vivo Capital LLC bought a new position in shares of enGene in the fourth quarter worth approximately $6,264,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.